GSK’s RSV vaccine shows long-term efficacy in late-stage trial
(Reuters) -GSK on Wednesday said its vaccine for the respiratory syncytial virus (RSV), which recently won EU approval, showed strong long-term protection in older adults in a late-stage trial. The British drugmaker…
